Introduction
SCLC
DISEASE PROGRESSION, SOLID TUMOUR, SCLC
The Aurora kinases are a family of serine/threonine kinases that play a critical role in the regulation of mitosis and chromosome alignment, accurate chromosomal segregation, and cytokinesis [AZD2811, formerly designated AZD1152 hydroxyquinazoline pyrazole anilide (AZD1152 hQPA), is an intravenously administered, potent and selective inhibitor of AURKB activity [This first-in-human, phase 1 study was conducted to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dosing schedule, safety, tolerability, and pharmacokinetics (PK) of AZD2811 as second-line or later therapy in patients with advanced solid tumours (NCT02579226; also called REFMAL 390) with disease progression or intolerance to standard therapies, or for whom no standard of care existed. The study consisted of Part A (dose escalation) and Part B (dose expansion in patients with SCLC). Here we report the results of Part A.